CHORD Therapeutics Sàrl
Drug development for rare neurological diseases
CHORD Therapeutics is dedicated to repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation, to bring a new effective therapy to patients with life-threatening and severely disabling neurological diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
20.12.2021
Merck acquires Chord Therapeutics (startupticker.ch)
16.10.2020
Chord Therapeutics launches with USD 16 million Series A financing (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
CHORD Therapeutics Sàrl
Drug development for rare neurological diseases
Website:
www.chordtherapeutics.com/
Headquarter:
Plan-les-Ouates
Foundation Date:
February 2014
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Drug discovery